#ERLEADA
#$JNJ · Johnson & Johnson reports new ERLEADA data before and after surgery

Johnson & Johnson said ERLEADA given before and after surgery reduced the risk of recurrence or death by 62% compared with surgery alone in patients with high-risk prostate cancer. For shareholders,…

#stocks #investing
Johnson & Johnson reports new ERLEADA data before and after surgery
Johnson & Johnson said ERLEADA given before and after surgery reduced the risk of recurrence or death by 62% compared with surgery alone in patients with high-risk prostate cancer. For shareholders, this is an update on clinical data, but the source does not report a financial impact.
insiderpost.org
October 26, 2026 at 6:11 AM
October 25, 2026 at 6:22 PM
Johnson & Johnson's ERLEADA Prostate Cancer Result Counts a Rising PSA as an Event
..................
https://nile1.com/johnson-johnsons-erleada-prostate-cancer-result-counts-a-rising-psa-as-an-event/
..................
#androgenDeprivationTherapy #apalutamide #erleadaProstateCancer #esmo2026 #halda
October 24, 2026 at 5:45 PM
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide…
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free…
news-area.com
October 25, 2026 at 12:58 AM
In case you missed it: Bayer sues Johnson & Johnson, alleging false advertising of Erleada harmed Nubeqa sales in competitive prostate cancer market.
March 2, 2026 at 11:00 AM
Bayer sues Johnson & Johnson, alleging false advertising of Erleada harmed Nubeqa sales in competitive prostate cancer market.
Bayer sues J&J over prostate cancer drug ads - NJBIZ
Bayer sues Johnson & Johnson, alleging false advertising of Erleada harmed Nubeqa sales in competitive prostate cancer market.
bit.ly
February 27, 2026 at 11:00 AM
Assessment of Apalutamide Metabolic Stability in HLMs Matrix Using a Sensitive and Fast UPLC‐MS/MS Method: In Silico Screening for Toxicity Alerts and Metabolic Lability #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
Assessment of Apalutamide Metabolic Stability in HLMs Matrix Using a Sensitive and Fast UPLC‐MS/MS Method: In Silico Screening for Toxicity Alerts and Metabolic Lability
Apalutamide (Erleada) is an oral androgen receptor antagonist that inhibits androgen action, reducing cancer cell growth. The FDA approved apalutamide (APD) for metastatic castration-sensitive prosta...
analyticalsciencejournals.onlinelibrary.wiley.com
January 27, 2026 at 8:41 AM
[2/3] risk of death from prostate cancer in half. In a ruling late Friday, U.S. District Judge Dale Ho in Manhattan said Bayer had failed to show it was likely to prevail on claims including that Johnson & Johnson's publicity for its drug Erleada caused irreparable harm and threatened
April 17, 2026 at 11:50 PM
nubeqa
xtandi
erleada
zytiga
February 12, 2026 at 3:56 PM
www.yahoo.com/news/article...

May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved th...
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and r...
www.yahoo.com
May 31, 2026 at 6:43 PM
Bayer sues J&J over ‘deeply flawed’ promotional claims touting Erleada over Nubeqa, prostate cancer drugs.
Bayer sues J&J over ‘deeply flawed’ promotional claims touting Erleada over Nubeqa
Bayer has filed a false advertising lawsuit, taking issue with claims made by Johnson & Johnson to pit their prostate cancer drugs against one another. | Bayer has filed a false advertising lawsuit ta...
www.fiercepharma.com
February 24, 2026 at 3:05 PM
#Apalutamid (ERLEADA): Interaktion mit Antihypertensiva

Ein Patient mit seit Jahren gut eingestellter #Hypertonie bemerkt einen massiven Blutdruckanstieg. Ist das von ihm seit fünf Tagen eingenommene Antiandrogen Apalutamid die Ursache?
www.arznei-telegramm.com/de/6481/apal...
Apalutamid (ERLEADA): Interaktion mit Antihypertensiva
Das arznei-telegramm informiert - unabhängig. kritisch. anzeigenfrei.
www.arznei-telegramm.com
April 29, 2026 at 6:27 AM
Italia – Agenti antineoplastici e immunomodulatori – PROCEDURA NEGOZIATA PER LA FORNITURA DEL FARMACO ERLEADA DELLA DITTA JANSSEN CILAG SPA PER LA DURATA DI 36 MESI A FAVORE DELL’AZIENDA SANITARIA DELL’ALTO ADIGE Stazione appaltante: Azienda Sanitaria Dell’alto Adige - Ripartizione Acquisti
Italia – Agenti antineoplastici e immunomodulatori – PROCEDURA NEGOZIATA PER LA… – Azienda Sanitaria Dell’alto Adige - Ripartizione Acquisti
## Riepilogo OggettoItalia – Agenti antineoplastici e immunomodulatori – PROCEDURA NEGOZIATA PER LA FORNITURA DEL FARMACO ERLEADA DELLA DITTA JANSSEN CILAG SPA PER LA DURATA DI 36 MESI A FAVORE DELL’AZIENDA SANITARIA DELL’ALTO ADIGE Stazione appaltanteAzienda Sanitaria Dell’alto Adige - Ripartizione Acquisti TED IDd60efe56-cce5-4c72-9cf5-873bf1b968cc ### This post is for subscribers only Become a member to get access to all content Subscribe now
vistagare.it
March 14, 2026 at 12:21 AM
Mon news: ASCO: AZ's Imfinzi, Imjudo duo shines in early stage liver cancer. Moderna partners with CEPI on Ebola vaccine efforts. J&J breaks the prostate cancer treatment mold with fresh Erleada win. Lilly’s Verzenio gives hope of liposarcoma treatment. —https://bit.ly/3JeBlY5
June 1, 2026 at 4:23 PM
📊 Top 3 drugs searched on DRUGDOCS® in March:

1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Esbriet® – Antifibrotic agent for idiopathic pulmonary fibrosis
3️⃣ Erleada® – Prostate cancer therapy

Explore the clinical evidence: drugdocs.com
April 8, 2026 at 8:17 PM
📊 Top 3 drugs searched on DRUGDOCS® in January:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Erleada® – Prostate cancer therapy
3️⃣ Avastin® – Anti-VEGF oncology mainstay

Explore the clinical evidence: drugdocs.com
February 9, 2026 at 4:47 PM
New study from @roosterjish.bsky.social @portalresearch.bsky.social @publiccitizen.bsky.social: which drugs are candidates for considering government march-in rights if found that excessive prices are affecting patient access (e.g., Xtandi, Erleada, Vyndamax): www.healthaffairs.org/content/fore...
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights | Health Affairs Forefront
March-in rights are vital safeguards that allow the federal government to license competitors when the owner is not making a taxpayer-funded invention reasonably available or cannot meet public health...
www.healthaffairs.org
November 21, 2024 at 1:57 PM